LPCN Company Profile and Key Details

Q: Who are the executives of LPCN?

Dr. Nachiappan Chidambaram Ph.D.Senior Vice President of R&DMs. Krista FogartyPrincipal Accounting Officer & Corporation ControllerMr. Logan MorseVice President of Sales, Marketing & OperationsDr. Anthony DelConte M.D., M. D.Chief Medical DirectorMr. Nachiappan Chidambaram Ph.D.Vice President of Product Devel.Dr. Mahesh V. Patel Ph.D.Co-Founder, Interim Principal Financial Officer, Director, Pres & Chief Executive OfficerDr. George G. Nomikos M.D., Ph.D.Senior Vice President of Medical & Clinical Sciences and Head of Muscle Therapeutic Area

NASDAQ : LPCN

Lipocine

$2.05

-7.2-77.84%

At Close 4:00 PM

64.34

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Lipocine Inc. (LPCN) stock declined over -77.84%, trading at $2.05 on NASDAQ, down from the previous close of $9.25. The stock opened at $2.06, fluctuating between $1.82 and $2.10 in the recent session.

Stock Snapshot

9.25

Prev. Close

11.16M

Market Cap

1.815

Day Low

-1.16

P/E Ratio

-1.77

EPS (TTM)

-2.23

Cash Flow per Share

2.06

Open

5.45M

Number of Shares

2.1

Day High

96.97%

Free Float in %

3.83

Book Value

7.02M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	2.01	2.11	1.81	2.05	7.1M
Apr 01, 2026	7.94	9.30	7.60	9.25	171.17K
Mar 31, 2026	7.80	8.07	7.64	7.99	142.54K
Mar 30, 2026	7.17	7.71	7.17	7.58	134.78K
Mar 27, 2026	7.40	7.66	6.89	7.15	65.12K
Mar 25, 2026	7.52	7.80	7.34	7.43	124.68K
Mar 24, 2026	7.24	7.56	7.16	7.36	71.94K
Mar 23, 2026	7.22	7.66	7.17	7.31	115.24K
Mar 20, 2026	7.31	7.35	6.91	7.15	78.55K
Mar 19, 2026	7.30	7.70	7.19	7.31	81.42K
Mar 18, 2026	7.66	7.97	7.29	7.30	69.2K
Mar 17, 2026	7.40	8.00	7.32	7.67	114.2K
Mar 16, 2026	7.34	7.76	7.22	7.29	47.3K
Mar 13, 2026	8.26	8.50	7.31	7.34	163.08K
Mar 12, 2026	8.97	9.25	7.95	8.05	258.14K
Mar 11, 2026	8.19	9.28	8.07	8.99	102.22K
Mar 10, 2026	7.95	8.75	7.95	8.11	150.13K
Mar 09, 2026	8.04	8.35	7.88	7.88	26.35K
Mar 06, 2026	8.00	8.31	7.81	8.13	61.64K
Mar 03, 2026	8.75	8.75	8.35	8.42	65.54K

Contact Details

Salt Lake City, UT 84108

United States

https://www.lipocine.com 801 994 7383

About Company

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Stock Peers

REGN

-15.4-1.98%

Regeneron Pharmaceuticals, Inc.$761.85 ARGX

3.3+0.44%

argenx SE$746.42 UTHR

-5.46-0.96%

United Therapeutics Corporation$564.81 MDGL

17.05+3.22%

Madrigal Pharmaceuticals, Inc.$546.89 VRTX

-8.55-1.91%

Vertex Pharmaceuticals Incorporated$438.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-9.88-3.01%

Alnylam Pharmaceuticals, Inc.$318.85 PRAX

-8.9-2.79%

Praxis Precision Medicines, Inc.$310.38 KRYS

2.04+0.79%

Krystal Biotech, Inc.$260.95 ASND

1.01+0.44%

Ascendis Pharma A/S$229.25

Company Overview

Lipocine Inc. (NASDAQ:LPCN) closed at $2.05 USD, losing -$7.20 (-77.84%) from the previous close of $9.25. The stock is currently mid-range between its 52-week high and low $1.81 and $12.37. With a market capitalization of about $11.16 million, Lipocine Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.09). Key stats such as the average daily volume over the past year has been around 243.86 thousand shares, trading with heavier-than-usual volume. Headquartered in Salt Lake City, UT, Lipocine Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mahesh V. Patel, the company employs approximately 16 people and listed since October 22, 2013. Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders.

Technical Performance

LPCN has shown sold momentum, gaining 9.86% over the past week and 228.48% over the past quarter, though year-to-date performance is up 23.54%. Short-term trend indicators are bearishly aligned (SMA20 11.2%, SMA50 22.49%, SMA200 129.24%). The stock’s 14-day RSI is 62.52 (firm momentum), while the ATR of 0.85 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.16% below its high and over 296.83% above its low. Average 10-day trading volume of 1.12 million shares is significantly above the 3-month average of 248.00 thousand, indicating heightened recent market interest.

Valuation Metrics

Lipocine Inc. trades at a P/E ratio of -1.16, slightly below the S&P 500 average, with a price-to-sales ratio of 5.65 and a price-to-book ratio of 0.77 suggesting the stock is closer to book value. The P/FCF stands at -1.14, also above market averages.

Dividend & Fair Value

Lipocine Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.91. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Lipocine Inc. generated EPS of -$1.02 over the past year. Five-year average earnings growth is 82.03%. The latest quarter delivered EPS of -$0.59. The next quarter is forecast at -$0.61. Next year's EPS is expected at $44.15. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $7.00. The high target offers 631.71% upside. The low target suggests 241.46% downside. The mean target is $9.50. This offers 363.41% upside. Lipocine Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 5.13%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -26.38% in August 08, 2024.

Shareholding & Insider Activity

Lipocine Inc. has 5.42 million shares outstanding. The public float is 5.26 million shares, elevated short interest at 1.89% of float. This equals 98.44 thousand shares. The short ratio is 2.66 days. Institutional investors hold 10.1% of the float. Insiders own 2.91%. Higuchi John W. holds 693.55 thousand shares, BROWN MORGAN R has 194.50 thousand shares and Patel Mahesh V. has 135.68 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Lipocine generated $109.99K in revenue, or $0.02 per share. Gross margin was 73.94%, operating margin -13610.84%, and net profit margin -14867.29%. Returns are negative, with ROA at -71.09% and ROE at -80.28%.
On valuation metrics, Lipocine trades at a P/E of -1.16, P/S of 5.65 and P/B of 0.77. The current ratio is 6.68 and quick ratio is 6.68. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -162.23 days , indicating it collects cash faster than it pays suppliers.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Lipocine posted revenue of $109.99K, down slightly from $500.00K in the prior quarter. Gross profit was $81.33K (margin 73.94%). Operating income was - $14.97M (margin -13610.8%). Net income was- $16.35M (EPS - $3.10).
The company ended the quarter with $22.04M in cash and short-term investments, a total debt of $17.17K, and net debt of - $4.75M. Total assets were $23.00M, with equity of $20.37M. Financials further reflected weakness, with operating cash flow of - $11.87M, free cash flow of - $11.88M, and capital expenditures of - $13.17K.

Price Forecast & Outlook

Our AI price prediction model suggests that Lipocine Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 113.66%, with price expected at $4.38 by April 16, 2026, within a range of $3.18 to $5.66 3-Month Outlook: Projected rise of 413.17%, reaching $10.52 by July 01, 2026, with a range of $10.34 to $10.69. 1-Year Outlook: Projected gain of 1344.39%, with price at $29.61 by April 02, 2027, within a range of $30.63 to $35.74.

Key Takeaways

Lipocine Inc. (NASDAQ:LPCN) shares are up 23.54% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Lipocine Inc. trading at a premium to the broader market with a P/E of -1.16. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.71, suggesting 520.0% upside. Our AI forecast model points to short-term strength (113.66% over two weeks), a medium-term rise (413.17% over three months), and a longer-term gain (1344.39% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Lipocine Inc. (LPCN) stock price?

Lipocine Inc. (NASDAQ: LPCN) stock price is $2.05 in the last trading session. During the trading session, LPCN stock reached the peak price of $2.10 while $1.82 was the lowest point it dropped to. The percentage change in LPCN stock occurred in the recent session was -77.84% while the dollar amount for the price change in LPCN stock was - $7.20.

LPCN's industry and sector of operation?

The NASDAQ listed LPCN is part of Biotechnology industry that operates in the broader Healthcare sector. Lipocine Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LPCN?

Dr. Nachiappan Chidambaram Ph.D.
Senior Vice President of R&D
Ms. Krista Fogarty
Principal Accounting Officer & Corporation Controller
Mr. Logan Morse
Vice President of Sales, Marketing & Operations
Dr. Anthony DelConte M.D., M. D.
Chief Medical Director
Mr. Nachiappan Chidambaram Ph.D.
Vice President of Product Devel.
Dr. Mahesh V. Patel Ph.D.
Co-Founder, Interim Principal Financial Officer, Director, Pres & Chief Executive Officer
Dr. George G. Nomikos M.D., Ph.D.
Senior Vice President of Medical & Clinical Sciences and Head of Muscle Therapeutic Area

How LPCN did perform over past 52-week?

LPCN's closing price is 13.26% higher than its 52-week low of $1.81 where as its distance from 52-week high of $12.37 is -83.43%.

How many employees does LPCN have?

Number of LPCN employees currently stands at 16.

Link for LPCN official website?

Official Website of LPCN is: https://www.lipocine.com

How do I contact LPCN?

LPCN could be contacted at phone 801 994 7383 and can also be accessed through its website. LPCN operates from 675 Arapeen Drive, Salt Lake City, UT 84108, United States.

How many shares of LPCN are traded daily?

LPCN stock volume for the day was 7.02M shares. The average number of LPCN shares traded daily for last 3 months was 243.86K.

What is the market cap of LPCN currently?

The market value of LPCN currently stands at $11.16M with its latest stock price at $2.05 and 5.45M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	16
Beta	1.01
Sales or Revenue	$109.99K
5Y Sales Change%	-2.576%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

LPCN Company Profile and Key Details

Lipocine

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Dividend & Fair Value

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways